CAJ | 학술논문

目的：分析高通量血液透析及高通量血液透析滤过对骨及矿物质代谢的价值。方法收集2012年12月～2013年12月本院收治的60例维持性血液透析的终末期肾脏病患者临床资料，高通量血液透析（HFHD）治疗后高通量血液透析滤过（HFHDF）治疗，比较HFHD、HFHDF后1、3、6个月后各项治疗指标变化。结果 HFHD与HFHDF后1、3、6个月后，患者BMI、收缩压、舒张压、Kt /V 、BUN、Scr、UA、ALB比较，差异无统计学意义（P＞0.05）。HFHD与HFHDF后1、3个月，患者血清钙、血清磷、甲状旁腺激素比较，差异无统计学意义（P＞0.05）。HFHDF 后6个月血清磷、甲状旁腺激素水平均明显低于HFHD，两组差异有统计学意义（P＜0.05）；血清钙水平亦低于HFHD，两组差异无统计学意义（P＞0.05）。结论给予终末期肾脏病患者使用高通量血液透析滤过，有利于降低血磷水平，改善继发性甲状旁腺功能亢进，改善患者预后情况，值得临床推广。
목적：분석고통량혈액투석급고통량혈액투석려과대골급광물질대사적개치。방법수집2012년12월～2013년12월본원수치적60례유지성혈액투석적종말기신장병환자림상자료，고통량혈액투석（HFHD）치료후고통량혈액투석려과（HFHDF）치료，비교HFHD、HFHDF후1、3、6개월후각항치료지표변화。결과 HFHD여HFHDF후1、3、6개월후，환자BMI、수축압、서장압、Kt /V 、BUN、Scr、UA、ALB비교，차이무통계학의의（P＞0.05）。HFHD여HFHDF후1、3개월，환자혈청개、혈청린、갑상방선격소비교，차이무통계학의의（P＞0.05）。HFHDF 후6개월혈청린、갑상방선격소수평균명현저우HFHD，량조차이유통계학의의（P＜0.05）；혈청개수평역저우HFHD，량조차이무통계학의의（P＞0.05）。결론급여종말기신장병환자사용고통량혈액투석려과，유리우강저혈린수평，개선계발성갑상방선공능항진，개선환자예후정황，치득림상추엄。
ObjectiveTo analyze of the value of high flux hemodialysis and high flux hemodiafiltration on bone and mineral metabolism.MethodsThe clinical data of 60 cases with maintenance hemodialysis patients with end-stage renal disease were collected from December 2012 to December 2013 in our hospital. After the high-flux hemodialysis (HFHD) treatment,all the patients were given high-throughput hemodiafiltration (HFHDF) treatment, changes in the index of HFHD, after HFHDF 1 month, 3 months, six months were compared.ResultsThere was no significant difference in BMI, systolic blood pressure, diastolic blood pressure, Kt /V, BUN, Scr, UA, ALB among HFHD and after HFHDF 1 months, 3 months, 6months(P>0.05). There was no significant difference in the serum calcium, phosphorus and parathyroid hormone among HFHD and HFHDF 1 months, 3 months(P>0.05). The serum phosphorus and parathyroid hormone after HFHDF 6 months was lower than HFHD,there was significant difference (P<0.05). The serum calcium levels was lower than HFHD, but there was no significant difference (P>0.05). ConclusionPatients with end-stage renal disease using high flux hemodiafiltration, it can reduce blood phosphorus level, improve the secondary hyperparathyroidism and the prognosis. It is worthy of clinical promotion.